Patent Incentives Pitched As Part Of Corporate Tax Reform
This article was originally published in The Pink Sheet Daily
European-style 'patent box' recommended by former Allergan CEO at Senate hearing.
You may also be interested in...
The year 2014 was the biggest for pharma M&A in recent history, though it may be remembered equally for sagas and upsets that never materialized into finalized deals. Actavis, in the end, was the most aggressive acquirer, buying Forest and Allergan for a total of $89.3 billion in the two most expensive deals of the year.
Venture capitalist suggests the agency should keep both issues in mind when it orders a sponsor to conduct more trials or submit additional data in order to bring down the cost of drug development.
GlaxoSmithKline is to invest £500 million in new U.K. manufacturing facilities in Ulverston, Montrose and Irvine, creating 1,000 jobs in the process.